AzTrials
AzTrials

Sleep DisordersNCT06755593

Intravascular Laser and Electroacupuncture for Sciatica With Insomnia: A Pilot Trial

A study testing Electroacupuncture and Intravascular Low-Level Laser Therapy (ILIB) in people with Sleep Disorders and Sciatica, run by Le Hoang Minh Quan at 1 site in Vietnam.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Sciatica is a common condition worldwide, with prevalence rates ranging from 1.2% to 43%. Chronic sciatica is often associated with sleep disturbances, forming a bidirectional loop where persistent nociceptive input disrupts sleep continuity, and sleep deprivation amplifies mechanical pain sensitivity. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Sleep Disorders, Sciatica
What is being tested?
Electroacupuncture and Intravascular Low-Level Laser Therapy (ILIB)
Could I receive a placebo?
No, everyone receives an active treatment
How many people
66 participants
Where
1 siteVietnam
Study dates
1 Apr 2025to 1 Dec 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Adults aged ≥ 18 years.
  • Diagnosis of chronic sciatica pain lasting ≥ 3 months.
  • Sleep disturbance defined by a Pittsburgh Sleep Quality Index (PSQI) score > 5.
  • Pain intensity score ≥ 50 mm on a 100-mm Visual Analog Scale (VAS).
  • Able to walk independently (with or without walking aids).
  • Provided written informed consent to participate in the study.

Who cannot join

  • Malignant diseases, autoimmune diseases, or systemic inflammatory disorders.
  • History of prior spinal surgery.
  • Acute low back pain of < 4 weeks' duration.
  • Primary sleep disorders (e.g., narcolepsy, sleep apnea, circadian rhythm disorders).
  • Diagnosed psychiatric conditions such as depression, anxiety, or delirium.
  • Current use of psychotropic, antidepressant, hypnotic, corticosteroid, or antihistamine medications.
Show all 9Show fewer
  • Contraindications to low-level intravascular laser irradiation (e.g., hemophilia, acute myocardial infarction, acute stroke within 72 hours, active infection, pregnancy).
  • Signs or suspicion of severe spinal conditions (e.g., cancer, vertebral fracture, spinal infection, or cauda equina syndrome).
  • Concurrent involvement of lumbosacral nerve roots, plexus, or peripheral neuropathy confirmed by electrodiagnostic testing.

Trial locations and contacts

1 site in 1 country.

Vietnam1 site
  • Binh Dinh Traditional Medicine and Rehabilitation Hospital

    Qui Nhon, Binh Dinh, 55100

Other trials in Vietnam

About this study

Official title: Effectiveness of Intravenous Laser Therapy in Patients With Sciatica and Sleep Disorders at Binh Dinh Hospital of Traditional Medicine and Rehabilitation

Sciatica is a common condition worldwide, with prevalence rates ranging from 1.2% to 43%. Chronic sciatica is often associated with sleep disturbances, forming a bidirectional loop where persistent nociceptive input disrupts sleep continuity, and sleep deprivation amplifies mechanical pain sensitivity. According to institutional records, sciatica accounts for approximately 26% of hospital admissions for musculoskeletal disorders at regional rehabilitation centers. Current pharmacological options for sleep fragmentation provide limited benefits and carry risks of tolerance or dependence, making integrative, non-pharmacologic frameworks important.

Intravascular laser irradiation of blood (ILIB), or intravascular photobiomodulation, is a minimally invasive therapy delivering low-level red laser light (630 nm) into the venous circulation to downregulate systemic inflammation and improve microcirculation. This randomized controlled pilot study evaluates the operational feasibility and preliminary clinical trends of combining ILIB with standardized electroacupuncture. Sixty-six participants are randomly assigned to two parallel arms: a control group receiving electroacupuncture alone (n = 33) and an intervention group receiving combined ILIB and electroacupuncture (n = 33). Active treatment is administered daily for 10 sessions over 2 consecutive weeks. Clinical and behavioral parameters are tracked via the Pittsburgh Sleep Quality Index (PSQI), Visual Analog Scale (VAS) for pain, Oswestry Disability Index (ODI), Epworth Sleepiness Scale (ESS), and patient medication diaries at baseline, Day 7, Day 15, and an exploratory post-treatment follow-up on Day 22.

Read the detailed description

Sciatica, characterized by radiating pain along the sciatic nerve, is one of the most common causes of chronic low back pain. The condition affects approximately 13%-40% of adults globally and remains a major contributor to disability, reduced productivity, and impaired quality of life. In Vietnam, hospital-based surveys have reported that sciatica accounts for 12%-26% of inpatient admissions in traditional medicine and rehabilitation facilities.

Chronic musculoskeletal pain such as sciatica is frequently associated with sleep disorders. Studies indicate that up to 70% of patients with chronic pain experience poor sleep quality, and the relationship between pain and sleep is bidirectional: persistent pain interferes with sleep continuity, while sleep deprivation increases pain sensitivity and emotional distress. Conventional pharmacologic treatments for insomnia (such as benzodiazepines or non-benzodiazepine hypnotics) often provide temporary relief but may cause tolerance, dependence, or adverse cognitive effects. Consequently, non-pharmacologic and integrative approaches are increasingly emphasized in chronic pain management.

Intravascular photobiomodulation (ILIB), also referred to as intravascular laser irradiation of blood, is a minimally invasive technique that introduces low-level laser light (typically 630-650 nm) into the venous circulation. The photobiological effects of ILIB include enhanced oxygen transport, improved microcirculation, modulation of oxidative stress, and anti-inflammatory action. Clinical studies have demonstrated ILIB's potential in various chronic diseases, including musculoskeletal pain, vascular disorders, and metabolic dysfunctions. Preliminary evidence also suggests that ILIB may enhance sleep quality through regulation of circadian and autonomic function.

This randomized controlled pilot study was designed to evaluate the short-term efficacy of ILIB combined with electroacupuncture in improving pain and sleep quality in patients with chronic sciatica. The trial was conducted at the Binh Dinh Hospital of Traditional Medicine and Rehabilitation, Vietnam, from January to December 2025.

A total of 66 patients aged 18 years or older, diagnosed with chronic sciatica (pain duration ≥ 3 months) and sleep disturbance (Pittsburgh Sleep Quality Index > 5), were recruited and randomly assigned to one of two groups:

  • Control Group (n = 33): Received standardized electroacupuncture at a continuous frequency of 60 Hz for 20 minutes per session, once daily for 10 sessions over 2 weeks. Acupuncture points targeted specific dermatomal roots matching the sciatic path: Jiaji (L3-S1), Dachangshu (BL25), Huantiao (GB30), Yinmen (BL37), Yanglingquan (GB34), Chengfu (BL36), Chengshan (BL57), and Kunlun (BL60).
  • Intervention Group (n = 33): Received the identical electroacupuncture regimen plus adjunctive low-level intravascular laser irradiation (wavelength: 630 nm; output power: 2.5 mW) administered continuously for 30 minutes per session, totaling 10 sessions.

To control for pharmacological confounding factors, participants were restricted from modifying baseline drug therapies or initiating non-protocol physical modalities. Permitted rescue analgesic medication was restricted to paracetamol (maximum 2 g/day), tracked quantitatively via daily patient compliance diaries. Outcome measures were logged across four temporal milestones: baseline (Day 0), Day 7, Day 15, and an exploratory post-treatment follow-up on Day 22 to examine short-term carry-over retention after treatment withdrawal. Longitudinal data analysis was performed using linear mixed-effects regression models to handle repeated measurements while protecting statistical transparency.

Being tested
Electroacupuncture, Intravascular Low-Level Laser Therapy (ILIB)
Keywords
sciatica, sleep disorders, intravenous laser, electroacupuncture
Medical subject headings
Sleep Wake Disorders, Sciatica

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ElectroacupunctureProcedure or surgery

    Electroacupuncture is performed using sterile disposable acupuncture needles (0.30 × 25 mm) connected to an electroacupuncture stimulator (KWD808-1, Gujin Greatwall, China). Stimulation is applied at a frequency of 60 Hz for 20 minutes per session. Treatment is performed once daily for 10 consecutive days. Acupuncture points include Jiaji (L3-S1), Dachangshu (BL25), Huantiao (GB30), Yinmen (BL37), Yanglingquan (GB34), Chengfu (BL36), Chengshan (BL57), and Kunlun (BL60).

  • Intravascular Low-Level Laser Therapy (ILIB)Device

    Intravascular laser irradiation of blood (ILIB) is administered using a helium-neon laser device (Mini-630, 635 nm wavelength) manufactured by the Vietnam Laser Technology Center. A sterile optical fiber is inserted into a peripheral vein via a standard intravenous needle. The laser is connected to the fiber to deliver continuous photobiomodulation for 30 minutes per session, 5 sessions per week, for 2 consecutive weeks (10 sessions total). This device is used only in the experimental group in combination with electroacupuncture.

Study groups in NCT06755593
Study groupRoleWhat they receive
Electroacupuncture and intravenous laserExperimentalParticipants in this group receive combined electroacupuncture and intravascular laser irradiation of blood (ILIB). * Electroacupuncture: Performed once daily for 10 consecutive days at a frequency of 60 Hz, 20 minutes per session. Acupuncture points include Jiaji (L3-S1), Dachangshu (BL25), Huantiao (GB30), Yinmen (BL37), Yanglingquan (GB34), Chengfu (BL36), Chengshan (BL57), and Kunlun (BL60). * Intravascular Laser Therapy: A sterile intravenous needle is inserted into a peripheral vein, and a laser fiber (630-650 nm, low-level laser) is introduced through the same entry site. The laser is connected to the laser source, delivering photobiomodulation for 30 minutes per session, 5 sessions per week, for 2 consecutive weeks (total 10 sessions). Intervention Name: * Procedure: Electroacupuncture * Device: Intravascular Low-Level Laser Therapy (ILIB)
Receives: Procedure: Electroacupuncture; Device: Intravascular Low-Level Laser Therapy (ILIB)
ElectroacupunctureActive comparatorParticipants in this group receive electroacupuncture only. * Electroacupuncture: Performed once daily for 10 consecutive days, 20 minutes per session, using a frequency of 60 Hz. * Acupuncture Points: Jiaji (L3-S1), Dachangshu (BL25), Huantiao (GB30), Yinmen (BL37), Yanglingquan (GB34), Chengfu (BL36), Chengshan (BL57), and Kunlun (BL60). Intervention Name: - Procedure: Electroacupuncture
Receives: Procedure: Electroacupuncture

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Recruitment Velocity

    The programmatic feasibility of patient acquisition calculated as the percentage of successfully randomized participants out of the total number of screened continuous adult outpatients presenting with persistent lumbar radiculopathy over the institutional trial window.

    Measured: From start of screening up to study primary completion (12 months).

  2. Protocol Treatment Adherence

    The operational adherence tracked as the percentage of successfully completed active intervention sessions out of the 10 scheduled combinations of electroacupuncture and intravascular photobiomodulation within the active treatment phase.

    Measured: Up to active treatment completion (Day 15).

  3. Longitudinal Cohort Retention Rate

    The percentage of randomized participants who remain fully evaluable and complete the final exploratory post-intervention follow-up matrix without dropping out.

    Measured: Up to the exploratory follow-up milestone (Day 22).

Secondary outcomes (5)
  1. Change in Pittsburgh Sleep Quality Index (PSQI) Score

    The Pittsburgh Sleep Quality Index (PSQI) is a self-reported questionnaire assessing sleep quality and disturbances over the previous month. It includes 19 items grouped into 7 components (subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction). Each component is scored from 0 to 3, and the global PSQI score ranges from 0 to 21, where higher scores indicate poorer sleep quality.

    Measured: Days 0 (baseline), 7, 15, and Day 22 (Exploratory Post-treatment follow-up).

  2. Change in Epworth Sleepiness Scale (ESS) Score

    The Epworth Sleepiness Scale (ESS) measures daytime sleepiness across eight daily situations, rated from 0 (no chance of dozing) to 3 (high chance of dozing). The total score ranges from 0 to 24, with higher scores indicating greater daytime sleepiness.

    Measured: Days 0 (baseline), 7, 15, and Day 22 (Exploratory Follow-up).

  3. Change in Visual Analog Scale (VAS) for Pain

    Pain intensity is measured using a 100-mm Visual Analog Scale (VAS), where 0 indicates "no pain" and 100 indicates "worst imaginable pain." Scores are categorized as follows: 0-1 (no pain), 1-4 (mild), 4-6 (moderate), >6 (severe). The change in VAS from baseline to each follow-up point will be analyzed.

    Measured: Days 0 (baseline), 7, 15, and Day 22 (Exploratory Follow-up).

  4. Change in Oswestry Disability Index (ODI)

    The Oswestry Disability Index (ODI) is a standardized questionnaire that measures the degree of disability related to low back pain. It consists of 10 sections, each scored from 0 to 5. The total score is expressed as a percentage from 0% to 100%, where 0% indicates no disability and 100% indicates maximum disability. Higher scores represent worse functional impairment.

    Measured: Days 0 (baseline), 7, 15, and Day 22 (Exploratory Follow-up).

  5. Cumulative Rescue Analgesic Requirements

    Behavioral drug reliance derived from structured patient diaries, logged mathematically as cumulative weekly paracetamol intake to assess treatment dependence variations between the parallel arms.

    Measured: Week 1 (Days 1-7), Week 2 (Days 8-15), and Week 3 (Days 16-22; Post-treatment tracking).

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Jan 2025
  2. Study start1 Apr 2025
  3. Primary completion1 Dec 2025
  4. Study completion1 Dec 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
A Pilot Trial
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
66 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06755593
Sponsor's protocol ID
445/QĐ-SYT
Status last verified
Jun 2026
First submitted
24 Dec 2024
Last updated
1 Jul 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Individual participant data (IPD) that will be shared include: demographic characteristics (age, sex, BMI, occupation) and de-identified outcome data related to pain, sleep quality, disability, and daytime sleepiness (VAS, PSQI, ODI, ESS). No identifiable personal information will be shared.

Questions about this trial

What is this clinical trial studying?

A study testing Electroacupuncture and Intravascular Low-Level Laser Therapy (ILIB) in people with Sleep Disorders and Sciatica, run by Le Hoang Minh Quan at 1 site in Vietnam.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 1 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Vietnam. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Recruitment Velocity (time frame: From start of screening up to study primary completion (12 months).). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Jul 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in